Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enovis Corporation Common Stock (NY:ENOV)

37.43 -0.78 (-2.04%)
Streaming Delayed Price Updated: 12:51 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Enovis Corporation Common Stock

< Previous 1 2 Next >
2 Healthcare Stocks with Solid Fundamentals and 1 to Turn Down
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
3 Stocks Under $50 in the Doghouse
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some... 
Via StockStory
Medical Devices & Supplies - Specialty Stocks Q4 In Review: Globus Medical (NYSE:GMED) Vs Peers
Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers. 
Via StockStory
A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q3 Earnings: STAAR Surgical (NASDAQ:STAA) Vs The Rest Of The Pack
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQ:STAA) and the best... 
Via StockStory
Earnings Scheduled For February 26, 2025
Via Benzinga
The Latest Analyst Ratings For Enovis
Via Benzinga
Enovis (NYSE:ENOV) Exceeds Q4 Expectations
Medical technology company Enovis Corporation (NYSE:ENOV) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 23.3% year on year to $561 million. On the other hand, the... 
Via StockStory
Enovis (ENOV) Q4 Earnings: What To Expect
Medical technology company Enovis Corporation (NYSE:ENOV) will be announcing earnings results tomorrow before market open. Here’s what to expect. 
Via StockStory
Instacart Grows Stronger: S&P MidCap 400 Inclusion, Ulta Partnership Boosts Stock
Instacart gains as it is set to join S&P MidCap 400. The company also partners with Ulta Beauty for same-day delivery, boosting stock value. 
Via Benzinga
Topics Stocks
Exposures US Equities
Instacart Stock Jumps. It'll Join The S&P MidCap 400 Index.
The grocery delivery company will soon join the S&P MidCap 400 index. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Orthopedic Implant Player Enovis' M&A Strategy Core To Growth And Competitiveness, Analyst Says
JMP Securities initiates coverage on Enovis Corporation with a Market Outperform rating, highlighting its strategic acquisitions, including LimaCorporate, and future growth potential. The analyst notes... 
Via Benzinga
Critical Insights From Enovis Analyst Ratings: What You Need To Know
Via Benzinga
A Closer Look at 6 Analyst Recommendations For Enovis
Via Benzinga
ENOV Stock Earnings: Enovis Beats EPS, Misses Revenue for Q2 2024
ENOV stock results show that Enovis beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Top 3 Health Care Stocks That Could Blast Off In June
Via Benzinga
5 Medical Info Systems Stocks To Buy For Stable Returns
The medical info systems industry is thriving due to the growing demand for contactless services. Amid this environment, here are some stocks in the industry that may see stable returns in 2024. 
Via Talk Markets
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
ENOV Stock Earnings: Enovis Beats EPS, Beats Revenue for Q1 2024
ENOV stock results show that Enovis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Medtech Firm Enovis Sets Strong 2024 Targets As Q4 Earnings Beat Expectations, Analyst Says Growth Intact
Enovis reports Q4 results with net sales surging 11% YoY, reaching $455 million. The growth is attributed to strong performance in P&R and above-market expansion in Recon, coupled with recent... 
Via Benzinga
Topics Earnings
Exposures Financial
Earnings Outlook For Enovis
Via Benzinga
5 Analysts Have This To Say About Enovis
Via Benzinga
The Analyst Landscape: 6 Takes On Enovis
Via Benzinga
This Analyst Sees Durable Share Gains, Margin Expansion For Orthopedics-Focused Enovis
William Bliar has initiated coverage on Enovis Corp (NYSE: ENOV), a medical technology company focusing on the orthopedics market valued at approximately $25 billion, experiencing steady growth,... 
Via Benzinga
This Analyst Selects Enovis As Top Pick For 2024: Spotlight On EMPOWR Revision Launch
Needham analyst Mike Matson reiterated the Buy rating on Enovis Corporation (NYSE: ENOV), raising  
Via Benzinga
Analyst Ratings for Enovis
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2023
Via Benzinga
4 Analysts Have This to Say About Enovis
Via Benzinga
Why Enovis Stock Is Trading Lower Today
Enovis Corporation (NYSE: ENOV) shares are trading lower on Thursday after the company announced a proposed private offering of $400 million of convertible senior notes and issued 
Via Benzinga
Big Moves In Orthopedics: Enovis Seals €800M Deal To Acquire LimaCorporate
Enovis Corp (NYSE: ENOV) inked a deal to acquire LimaCorporate S.p.A. for an 
Via Benzinga
Enovis Above-Market Growth Potential Surge Would Come from Market Share Gains and Accretive Acquisitions: Analyst
Needham initiated coverage on Enovis Corp (NYSE: ENOV) with a Buy and a price target of $70, noting that the company can sustain above-market growth in its Reconstructive segment via market share gains... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.